An interventional study of Probiotic and Placebo in Pregnancy, Prematurity and PPROM, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Premature Birth with a site in Canada — 26 open to participants now, 34 under way, 2 of them phase 3. Premature Birth · Canada.
Among the 139 studies in Premature Birth with a site in Canada, this one is the 53rd largest by planned enrollment of the 106 interventional ones that give a count, is one of 7 that started in 2026, is one of 65 with no phase, reaches primary completion later than 23 of the 33 other live ones, and was the 129th registered.
2,556 studies on the registry are indexed under Premature Birth; 503 are open to participants now.
Browse Premature Birth studies →26 of the 139 studies in Premature Birth with a site in Canada are open now. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages up to 29 wk
Michelle Baczynski · Sites in Canada, United States, Denmark
Ages 25 wk–29 wk
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 28 wk–32 wk
Hamilton Health Sciences Corporation · Sites in Canada
Ages up to 28 wk
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 317 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 225 (71%) stop at 75 or younger; 242 take children under 18; 104 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 17 · Phase 4 5
First in 1998; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 80 across the 106 interventional studies, 144 across the 33 observational. Of the 78 that completed or were terminated, 9 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 139 have an industry lead sponsor. The 10 most frequent:
Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.
Centre hospitalier de l'Université de Montréal (CHUM) has 2 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
5 of the studies in Premature Birth with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05114096McMaster UniversitySingle Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) | 2026-12-31 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07732257McGill University Health Centre/Research Institute of the McGill University Health CentreWireless MicroPremVitals Button Sensor in the NICU | 2027-01-30 |
| NCT05213806IWK Health CentreWithHolding Enteral Feeds Around Blood Transfusion (International) | 2027-03-31 |
| NCT07262385University of British ColumbiaCalmer Brains in Very Preterm Infants | 2027-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 139 studies in Premature Birth with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the feasibility of the randomized controlled trial (RCT).
Secondary objectives include comparing the microbiota of preterm babies born after premature rupture of membranes across study groups.
To achieve this, participants will be asked to:
Premature rupture of fetal membranes before labor (PPROM) accounts for 30% of preterm births. Since PPROM is strongly associated with ascending vaginal infection, antibiotics are recommended during the latent period (LP) (the interval between rupture and birth). While they prolong the LP and improve neonatal health, they also exacerbate pre-existing vaginal dysbiosis. The addition of vaginal probiotics (VP) helps stabilize the vaginal microbiota (VM) and increase Lactobacillus levels. By enhancing the presence of beneficial bacteria in the vagina, probiotics help restore the balance between beneficial and pathogenic microbes, potentially reducing uterine infection and improving the fetal intestinal microbiota.
Pathophysiological Hypotheses for Improving Neonatal Health
The use of VP may influence neonatal outcomes through three potential mechanisms:
i) Reduction of vaginal dysbiosis: Prolongs pregnancy and mitigates complications related to fetal immaturity (e.g., decreases risk of intraventricular hemorrhage).
ii) Reduction of intrauterine infection/inflammation: Lowers neonatal complications associated with inflammation (e.g., reduces incidence of cystic periventricular leukomalacia).
iii) Improvement of neonatal intestinal microbiota (NIM) through probiotic ingestion: Decreases complications linked to neonatal dysbiosis (e.g., reduces risk of necrotizing enterocolitis [NEC]).
Primary Objectives
To assess the validity of:
i) A recruitment rate > 35% ii) A treatment adherence rate > 80% iii) A sample attrition rate \< 5%
Secondary Objectives
Population Pregnant women aged 18 years or older giving birth at one of the eight centers participating in the study in Quebec and Ontario, Canada. Participants will be randomly assigned, in a blinded manner, to either the probiotic or placebo group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Probiotics is a mix of probiotic strains.
Other: Probiotic
Capsule of sugar, same appearance than the probiotic.
Other: Placebo
Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
Recruitment rate
To assess the feasibility of the study, each local site team will complete a dashboard documenting every individual met and informed about the study. This dashboard will be used to calculate the recruitment rate, using the formula: Recruitment rate = (Number of eligible patients - Number of patients who did not consent) / Number of eligible patients Additionally, the dashboard will track reasons for acceptance or refusal.
Time frame: 7 months
Feasability dashboard
The attrition rate will be explored to assess feasability of the study. Attrititon rate = (# participants who dropped out / total of participants).
Time frame: 7 months
Treatment adherence
Finally, number of caps took during the treatment phase will be reported to explore the adherence of treatment.
Time frame: 7 months
Probiotics primers
Evaluate the presence or absence of probiotics in the various samples, i.e. vaginal secretions, meconium and 7-day-old baby's stool, using specific primers to detect strains.
Time frame: From enrollement to infant 7th day of life
Plan to share: Yes — Study Protocol, Statistical Analysis Plan (SAP) and informed Consent Form (ICF). No data concerning individual participant will be shared or published.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: The supporting information will be shared before the end of the study.
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: start Sep 2025 → Dec 2026, primary completion Mar 2026 → Dec 2027 and completion May 2026 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre hospitalier de l'Université de Montréal (CHUM) →